Concord Drugs Limited

BSE:538965 Stock Report

Market Cap: ₹379.3m

Concord Drugs Management

Management criteria checks 3/4

Concord Drugs' CEO is Seelam Reddy, appointed in Aug 2021, has a tenure of 3.42 years. total yearly compensation is ₹6.00M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 28.61% of the company’s shares, worth ₹108.50M. The average tenure of the management team and the board of directors is 13.7 years and 4.9 years respectively.

Key information

Seelam Reddy

Chief executive officer

₹6.0m

Total compensation

CEO salary percentage100.0%
CEO tenure3.4yrs
CEO ownership28.6%
Management average tenure13.7yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Seelam Reddy's remuneration changed compared to Concord Drugs's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-₹5m

Jun 30 2024n/an/a

₹92k

Mar 31 2024₹6m₹6m

₹5m

Dec 31 2023n/an/a

₹10m

Sep 30 2023n/an/a

₹17m

Jun 30 2023n/an/a

₹13m

Mar 31 2023₹6m₹6m

₹10m

Dec 31 2022n/an/a

₹9m

Sep 30 2022n/an/a

₹8m

Jun 30 2022n/an/a

₹11m

Mar 31 2022₹4m₹4m

₹16m

Dec 31 2021n/an/a

₹19m

Sep 30 2021n/an/a

₹42m

Jun 30 2021n/an/a

₹38m

Mar 31 2021₹2m₹2m

₹33m

Dec 31 2020n/an/a

₹30m

Sep 30 2020n/an/a

₹4m

Jun 30 2020n/an/a

₹4m

Mar 31 2020₹1m₹1m

₹3m

Dec 31 2019n/an/a

₹4m

Sep 30 2019n/an/a

₹4m

Jun 30 2019n/an/a

₹4m

Mar 31 2019₹2m₹2m

₹4m

Compensation vs Market: Seelam's total compensation ($USD69.86K) is above average for companies of similar size in the Indian market ($USD41.99K).

Compensation vs Earnings: Seelam's compensation has been consistent with company performance over the past year.

CEO

Seelam Reddy (55 yo)

3.4yrs

Tenure

₹6,000,000

Compensation

Mr. Seelam Nagi Reddy served as Managing Director at Concord Drugs Limited until July 16, 2016 and served as its Compliance Officer. Mr. Reddy has been the Chairman and Whole-time Director of Concord Drugs...

Leadership Team

NamePositionTenureCompensationOwnership
Seelam Reddy
Chairman of the Board & MD3.4yrs₹6.00m28.61%
₹ 108.5m
Seelam Reddy
CFO & Whole-Time Directorno data₹2.40m9.51%
₹ 36.1m
Namratha Nagla
Company Secretary & Compliance Officerless than a year₹10.00kno data
Seelam Manoj Reddy
Whole-Time Directorno data₹2.40m16.28%
₹ 61.8m
P. Ramachandrudu
QC Manager19.7yrsno datano data
K. Prasad
Assistant Manager- Production25.6yrsno datano data
V. Sekhar
Production Manager - Tablets Division24.4yrsno datano data
M. Reddy
Production Manager (Syrups Division)7.8yrsno datano data

13.7yrs

Average Tenure

55yo

Average Age

Experienced Management: 538965's management team is seasoned and experienced (13.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Seelam Reddy
Chairman of the Board & MD21.8yrs₹6.00m28.61%
₹ 108.5m
Seelam Reddy
CFO & Whole-Time Director13.6yrs₹2.40m9.51%
₹ 36.1m
Seelam Manoj Reddy
Whole-Time Director3.4yrs₹2.40m16.28%
₹ 61.8m
Kommula Reddy
Non-Executive Independent Director5.8yrsno datano data
Nagavenkata Hareesh Solleti
Non-Executive Independent Director3.9yrsno datano data
Sumeela Kasu
Independent Director2.6yrsno datano data

4.9yrs

Average Tenure

35yo

Average Age

Experienced Board: 538965's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 03:27
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Concord Drugs Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution